ArticleMaterials today. Bio2025
PUFAs-enriched oil bodies as natural anti-osteoarthritis drug delivery platforms.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent degenerative condition that leads to cartilage degradation, joint pain, and functional impairment, with few effective treatment options available. Curcumin (Cur), a polyphenol with potential therapeutic benefits for OA, is constrained by its poor solubility and bioavailability. In this study, we developed an innovative Cur delivery platform utilizing flaxseed-derived oil bodies (OBs), which are naturally enriched with ω-3 polyunsaturated fatty acids (PUFAs) that exhibit significant anti-inflammatory and antioxidant characteristics. We demonstrated that OBs could efficiently encapsulate Cur via a pH-driven method, significantly improving its aqueous dispersibility and bioavailability. The Cur-loaded OBs (Cur/OBs) exhibited superior anti-inflammatory and antioxidative effects by reducing intracellular ROS, alleviating inflammation, and preventing chondrocyte apoptosis. Additionally, Cur/OBs promoted the polarization of M1 pro-inflammatory macrophages to M2 anti-inflammatory macrophages through the PPARγ/NF-κB signaling pathway. In an experimental rat OA model, Cur/OBs significantly mitigated the progression of OA, outperforming free Cur and OBs alone. These findings suggest that PUFAs-enriched OBs are an effective carrier for Cur, offering a synergistic therapeutic strategy for OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.